<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLONIDINE HYDROCHLORIDE- clonidine hydrochloride tablet </strong><br>DIRECT RX<br></p></div>
<h1>CLONIDINE HYDROCHLORIDE</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="La17f41f8-bb6b-4961-a6b4-de27a5b9eb2b"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION SECTION</h1>
<p class="First">Clonidine hydrochloride, USP is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg, and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base.</p>
<p>The following inactive ingredients are contained in these products: corn starch, D&amp;C yellow #10 Aluminum Lake, FD&amp;C yellow #6 Aluminum Lake (Sunset Yellow Lake), lactose monohydrate, magnesium stearate, and sodium starch glycolate.</p>
<p>Clonidine hydrochloride, USP is an imidazoline derivative and exists as a mesomeric compound. The chemical name is 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride. The following is the structural formula:</p>
<p><img alt="image description" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e6583ff5-0e03-470b-a986-35770aa0e80b&amp;name=clonidine%20hydro%20MODULE%201.jpg"></p>
<p>Clonidine hydrochloride, USP is an odorless, bitter, white, crystalline substance soluble in water and alcohol.</p>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="L752c42e5-e0bd-4359-a3c6-0bf8136cb959"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY SECTION</h1>
<p class="First">Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, heart rate, and blood pressure. Clonidine hydrochloride tablets act relatively rapidly. The patient’s blood pressure declines within 30 to 60 minutes after an oral dose, the maximum decrease occurring within 2 to 4 hours. Renal blood flow and glomerular filtration rate remain essentially unchanged. Normal postural reflexes are intact, therefore, orthostatic symptoms are mild and infrequent.</p>
<p>Acute studies with clonidine hydrochloride in humans have demonstrated a moderate reduction (15% to 20%) of <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in the supine position with no change in the peripheral resistance: at a 45° tilt there is a smaller reduction in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and a decrease of peripheral resistance. During long term therapy, <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> tends to return to control values, while peripheral resistance remains decreased. Slowing of the pulse rate has been observed in most patients given clonidine, but the drug does not alter normal hemodynamic response to exercise.</p>
<p>Tolerance to the antihypertensive effect may develop in some patients, necessitating a reevaluation of therapy.</p>
<p>Other studies in patients have provided evidence of a reduction in plasma renin activity and in the excretion of aldosterone and catecholamines. The exact relationship of these pharmacologic actions to the antihypertensive effect of clonidine has not been fully elucidated.</p>
<p>Clonidine acutely stimulates growth hormone release in both children and adults, but does not produce a chronic elevation of growth hormone with long-term use.</p>
<p>Pharmacokinetics: The pharmacokinetics of clonidine is dose-proportional in the range of 100 to 600 mcg. The absolute bioavailability of clonidine on oral administration is 70% to 80%. Peak plasma clonidine levels are attained in approximately 1 to 3 hours.</p>
<p>Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours. The half-life increases up to 41 hours in patients with severe impairment of renal function. Clonidine crosses the placental barrier. It has been shown to cross the blood-brain barrier in rats.</p>
<p>Following oral administration about 40% to 60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours. About 50% of the absorbed dose is metabolized in the liver. Neither food nor the race of the patient influences the pharmacokinetics of clonidine.</p>
<p>The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 ng/mL in patients with normal excretory function. A further rise in the plasma levels will not enhance the antihypertensive effect.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Ld529442f-140b-42e2-bb01-0c8a439b039a"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE SECTION</h1>
<p class="First">Clonidine hydrochloride tablets, USP are indicated in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Ldc4131d7-1b1c-4718-bf0f-98fcc3427575"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS SECTION</h1>
<p class="First">Clonidine hydrochloride tablets should not be used in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clonidine (see <a href="#LINK_be387b37-ee8d-4733-add6-ee8e6aafbd74">PRECAUTIONS</a></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="L7ab04eba-19d4-4185-b60c-7f0aea611e6d"></a><a name="section-5"></a><p></p>
<h1>WARNINGS SECTION</h1>
<p class="First">Withdrawal: Patients should be instructed not to discontinue therapy without consulting their physician. Sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> accompanied or followed by a rapid <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span> and elevated catecholamine concentrations in the plasma. The likelihood of such reactions to discontinuation of clonidine therapy appears to be greater after administration of higher doses or continuation of concomitant beta-blocker treatment and special caution is therefore advised in these situations. Rare instances of <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported after clonidine withdrawal. When discontinuing therapy with clonidine hydrochloride tablets, USP, the physician should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptomatology.</p>
<p>An excessive <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span> following discontinuation of clonidine therapy can be reversed by administration of oral clonidine hydrochloride or by intravenous phentolamine. If therapy is to be discontinued in patients receiving a beta-blocker and clonidine concurrently, the beta-blocker should be withdrawn several days before the gradual discontinuation of clonidine hydrochloride tablets.</p>
<p>Because children commonly have gastrointestinal illnesses that lead to <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, they may be particularly susceptible to <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertensive episodes</span> resulting from abrupt inability to take medication.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Ld5bf858f-1cd2-4239-8e5e-22f370d25321"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS SECTION</h1>
<p class="First">General</p>
<p>In patients who have developed localized contact sensitization to transdermal clonidine, continuation of transdermal clonidine or substitution of oral clonidine hydrochloride therapy may be associated with the development of a generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</p>
<p>In patients who develop an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to transdermal clonidine, substitution of oral clonidine hydrochloride may also elicit an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (including generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>).</p>
<p>The sympatholytic action of clonidine may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. There are post-marketing reports of patients with conduction abnormalities and/or taking other sympatholytic drugs who developed severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> requiring IV atropine, IV isoproterenol and temporary cardiac pacing while taking clonidine.</p>
<p>In <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> caused by <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, no therapeutic effect of clonidine hydrochloride tablets can be expected.</p>
<p>Information for Patients</p>
<p>Patients should be cautioned against interruption of clonidine hydrochloride tablets therapy without their physician’s advice.</p>
<p>Since patients may experience a possible sedative effect, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">accommodation disorder</span> with use of clonidine, caution patients about engaging in activities such as driving a vehicle or operating appliances or machinery. Also, inform patients that this sedative effect may be increased by concomitant use of alcohol, barbiturates, or other sedating drugs.</p>
<p>Patients who wear contact lenses should be cautioned that treatment with clonidine hydrochloride tablets may cause <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dryness of eyes</span>.</p>
<p>Drug Interactions</p>
<p>Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the hypotensive effect of clonidine may be reduced, necessitating an increase in the clonidine dose.</p>
<p>If a patient receiving clonidine is also taking neuroleptics, orthostatic regulation disturbances (e.g., <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>) may be induced or exacerbated.</p>
<p>Monitor heart rate in patients receiving clonidine concomitantly with agents known to affect sinus node function or AV nodal conduction, e.g., digitalis, calcium channel blockers, and beta-blockers. <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span> resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concomitantly with diltiazem or verapamil.</p>
<p>Amitriptyline in combination with clonidine enhances the manifestation of <span class="product-label-link" type="condition" conceptid="4270897" conceptname="Corneal lesion">corneal lesions</span> in rats (see Toxicology).</p>
<p>Based on observations in patients in a state of alcoholic <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential (QT-prolongation, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>) of high intravenous doses of haloperidol. Causal relationship and relevance for clonidine oral tablets have not been established.</p>
<p>Toxicology: In several studies with oral clonidine hydrochloride, a dose-dependent increase in the incidence and severity of spontaneous <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span> was seen in albino rats treated for six months or longer. Tissue distribution studies in dogs and monkeys showed a concentration of clonidine in the choroid.</p>
<p>In view of the <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span> seen in rats, eye examinations were performed during clinical trials in 908 patients before, and periodically after, the start of clonidine therapy. In 353 of these 908 patients, the eye examinations were carried out over periods of 24 months or longer. Except for some dryness of the eyes, no drug-related abnormal ophthalmological findings were recorded and, according to specialized tests such as electroretinography and macular dazzle, retinal function was unchanged.</p>
<p>In combination with amitriptyline, clonidine hydrochloride administration led to the development of <span class="product-label-link" type="condition" conceptid="4270897" conceptname="Corneal lesion">corneal lesions</span> in rats within 5 days.</p>
<p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p>
<p>Chronic dietary administration of clonidine was not carcinogenic to rats (132 weeks) or mice (78 weeks) dosed, respectively, at up to 46 or 70 times the maximum recommended daily human dose as mg/kg (9 or 6 times the MRDHD on a mg/m2 basis). There was no evidence of genotoxicity in the Ames test for mutagenicity or mouse micronucleus test for clastogenicity.</p>
<p>Fertility of male or female rats was unaffected by clonidine doses as high as 150 mcg/kg (approximately 3 times MRDHD). In a separate experiment, fertility of female rats appeared to be affected at dose levels of 500 to 2000 mcg/kg (10 to 40 times the oral MRDHD on a mg/kg basis, 2 to 8 times the MRDHD on a mg/m2 basis).</p>
<p>PregnancyTeratogenic Effects</p>
<p>Pregnancy Category C</p>
<p>Reproduction studies performed in rabbits at doses up to approximately 3 times the oral maximum recommended daily human dose (MRDHD) of clonidine hydrochloride tablets, USP produced no evidence of a teratogenic or embryotoxic potential in rabbits. In rats, however, doses as low as 1/3 the oral MRDHD (1/15 the MRDHD on a mg/m2 basis) of clonidine were associated with increased resorptions in a study in which dams were treated continuously from 2 months prior to mating. Increased resorptions were not associated with treatment at the same time or at higher dose levels (up to 3 times the oral MRDHD) when the dams were treated on gestation days 6 to 15. Increases in resorption were observed at much higher dose levels (40 times the oral MRDHD on a mg/kg basis; 4 to 8 times the MRDHD on a mg/m2 basis) in mice and rats treated on gestation days 1 to14 (lowest dose employed in the study was 500 mcg/kg).</p>
<p>No adequate, well-controlled studies have been conducted in pregnant women. Clonidine crosses the placental barrier (see <a href="#LINK_6d9e4123-f620-4dd9-a52b-9d6121eeb727">CLINICAL PHARMACOLOGY</a>, Pharmacokinetics). Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Nursing Mothers</p>
<p>As clonidine hydrochloride tablets, USP are excreted in human milk, caution should be exercised when clonidine hydrochloride is administered to a nursing woman.</p>
<p>Pediatric Use</p>
<p>Safety and effectiveness in pediatric patients have not been established in adequate and well-controlled trials (see <a href="#LINK_e46cf05a-7c1b-4bcc-82a8-f20629543536">WARNINGS</a>,  <a href="#LINK_e46cf05a-7c1b-4bcc-82a8-f20629543536">Withdrawal</a>).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="L29e55d2e-9520-4474-b072-b59084e2576c"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS SECTION</h1>
<p class="First">Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, occurring in about 40 of 100 patients; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, about 33 in 100; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, about 16 in 100; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and sedation, each about 10 in 100.</p>
<p>The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride tablets, but in many cases patients were receiving concomitant medication and a causal relationship has not been established.</p>
<p>Body as a Whole: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and withdrawal syndrome. Also reported were a weakly positive Coombs’ test and increased sensitivity to alcohol.</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, electrocardiographic abnormalities (i.e., sinus node arrest, <span class="product-label-link" type="condition" conceptid="4217221" conceptname="Nodal rhythm disorder">junctional bradycardia</span>, high degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>), orthostatic symptoms, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, Raynaud’s phenomenon, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Cases of <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> have been reported, both with and without the use of concomitant digitalis.</p>
<p>Central Nervous System: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4276054" conceptname="Delusional perception">delusional perception</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (including visual and auditory), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, other behavioral changes, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, and <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span> or <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p>Dermatological: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, mild transient abnormalities in liver function tests, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4032796" conceptname="Parotitis">parotitis</span>, pseudo-obstruction (including colonic pseudo-obstruction), salivary gland <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Genitourinary: Decreased sexual activity, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">difficulty in micturition</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>.</p>
<p>Hematologic: <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>.</p>
<p>Metabolic: <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, transient elevation of blood glucose or serum creatine phosphokinase, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg cramps</span> and muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>.</p>
<p>Oro-otolaryngeal: Dryness of the nasal mucosa.</p>
<p>Ophthalmological: <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">Accommodation disorder</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, burning of the eyes, decreased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, and <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dryness of eyes</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="L2231bab5-8fd7-4744-b8b7-ff187a7b41de"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE SECTION</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> may develop early and may be followed by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, decreased or <span class="product-label-link" type="condition" conceptid="4290597" conceptname="Absent reflex">absent reflexes</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>. The frequency of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> may be higher in children than adults. Large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> may result in reversible cardiac conduction defects or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> generally occur within 30 minutes to two hours after exposure. As little as 0.1 mg of clonidine has produced signs of toxicity in children.</p>
<p>There is no specific antidote for clonidine overdosage. Clonidine overdosage may result in the rapid development of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>; therefore, induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> with ipecac syrup is not recommended. Gastric lavage may be indicated following recent and/or large ingestions. Administration of activated charcoal and/or a cathartic may be beneficial. Supportive care may include atropine sulfate for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, intravenous fluids and/or vasopressor agents for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and vasodilators for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Naloxone may be a useful adjunct for the management of clonidine-induced <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; blood pressure should be monitored since the administration of naloxone has occasionally resulted in paradoxical <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Tolazoline administration has yielded inconsistent results and is not recommended as first-line therapy. Dialysis is not likely to significantly enhance the elimination of clonidine.</p>
<p>The largest <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> reported to date involved a 28-year old male who ingested 100 mg of clonidine hydrochloride powder. This patient developed <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> followed by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, semicoma, and <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span>. The patient fully recovered after intensive treatment. Plasma clonidine levels were 60 ng/ml after 1 hour, 190 ng/ml after 1.5 hours, 370 ng/ml after 2 hours, and 120 ng/ml after 5.5 and 6.5 hours. In mice and rats, the oral LD50 of clonidine is 206 and 465 mg/kg, respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="L54c1def0-66e8-4de0-a65f-522cc81d5296"></a><a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION SECTION</h1>
<p class="First">Adults: The dose of clonidine hydrochloride tablets, USP must be adjusted according to the patient’s individual blood pressure response. The following is a general guide to its administration.</p>
<p>Initial Dose: 0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose.</p>
<p>Maintenance Dose: Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses.</p>
<p>Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may benefit from a lower initial dose. Patients  should be carefully monitored. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine following dialysis.</p>
<p>For questions regarding this product call Actavis at 1-800-432-8534.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="La46f2c88-ddac-4b6c-8921-a8a249dc9f96"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED SECTION</h1>
<p class="First">Clonidine hydrochloride tablets, USP are supplied as follows:</p>
<p>0.1 mg — Each orange, round tablet imprinted with and 127 on one side and bisect on the other side contains 0.1 mg of clonidine hydrochloride USP and is supplied in bottles of 100 (NDC 0228-2127-10) and 500 (NDC 0228-2127-50).</p>
<p>0.2 mg — Each orange, round tablet imprinted with on one side and 128 and bisect on the other side contains 0.2 mg of clonidine hydrochloride USP and is supplied in bottles of 100 (NDC 0228-2128-10) and 500 (NDC 0228-2128-50).</p>
<p>0.3 mg — Each orange, round tablet imprinted with on one side and 129 and bisect on the other side contains 0.3 mg of clonidine hydrochloride USP and is supplied in bottles of 100 (NDC 0228-2129-10).</p>
<p>Dispense in a tight, light-resistant container as defined in the USP.</p>
<p>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).</p>
<p>Manufactured by: </p>
<p>Actavis Elizabeth LLC</p>
<p>200 Elmora Avenue</p>
<p>Elizabeth, NJ 07207 USA </p>
<p>40-9183 </p>
<p>Revised — July 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Lc5a3cb39-8aad-4b03-b2ec-3f380d712550"></a><a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><img alt="image description" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e6583ff5-0e03-470b-a986-35770aa0e80b&amp;name=clonidine%20hydro%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLONIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">clonidine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61919-266(NDC:0228-2127)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLONIDINE HYDROCHLORIDE</strong> (CLONIDINE) </td>
<td class="formItem">CLONIDINE HYDROCHLORIDE</td>
<td class="formItem">0.1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">R127</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61919-266-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61919-266-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61919-266-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070974</td>
<td class="formItem">01/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>DIRECT RX
							(079254320)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DIRECT RX</td>
<td class="formItem"></td>
<td class="formItem">079254320</td>
<td class="formItem">relabel(61919-266), repack(61919-266)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>679b5f11-23fb-4801-8273-2c4085f73995</div>
<div>Set id: e6583ff5-0e03-470b-a986-35770aa0e80b</div>
<div>Version: 1</div>
<div>Effective Time: 20141117</div>
</div>
</div> <div class="DistributorName">DIRECT RX</div></p>
</body></html>
